使用ANG1005靶向转移性乳腺癌，ANG1005是一种新型的肽-紫杉醇偶联物，可穿越血脑屏障（BBB）。
Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB).
作者信息
Li Fei, Tang Shou-Ching
机构信息
The Editorial Office of Genes & Diseases, Chongqing, 400046, China.
Georgia Cancer Center, Medical College of Georgia, Augusta University, GA, USA.
出版信息
Genes Dis. 2017 Feb 10;4(1):1-3. doi: 10.1016/j.gendis.2017.01.004. eCollection 2017 Mar.
We devoted this short interview piece with Dr Shou-Ching Tang at Augusta University to feature some promising results from a clinical phase II trial on a novel brain-penetrating peptide-paclitaxel-conjugate, ANG1005, in treating brain metastatic breast cancer. These results were presented by Dr. Tang at the recent annual meeting of the European Society for Medical Oncology (ESMO 2016 Congress). This development heralds an important step forward towards the development of effective chemotherapeutic agents, which can cross the blood-brain-barrier and effectively treat and prevent the brain metastatic cancers.
我们刊发了这段对奥古斯塔大学的唐守清博士的简短采访，介绍了一项关于新型脑穿透性肽-紫杉醇偶联物ANG1005治疗脑转移性乳腺癌的II期临床试验的一些有前景的结果。唐博士在最近的欧洲医学肿瘤学会年会（2016年ESMO大会）上展示了这些结果。这一进展标志着在开发能够穿越血脑屏障、有效治疗和预防脑转移性癌症的有效化疗药物方面向前迈出了重要一步。
Zotero 插件